NCT04099901View on ClinicalTrials.gov

Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

March 14, 2023

Study Completion Date

February 26, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Anakinra

Subjects will be treated with a daily dose of 300 mg anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).

DRUG

Placebos

Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).

Trial Locations (3)

Unknown

Amsterdam UMC, location AMC, Amsterdam

University Medical Center Groningen (UMCG), Groningen

Radboudumc, Nijmegen

All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

Dutch Cancer Society

OTHER

lead

Radboud University Medical Center

OTHER

NCT04099901 - Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial | Biotech Hunter | Biotech Hunter